Efficacy and Tumor-associated Markers Analysis of Chinese Medicine Combined with Paclitaxel and Carboplatin in the Treatment of Advanced Ovarian Cancer
CHEN Zhi-mei
Department of Obstetrics and Gynecologym, Tangcheng Hospital Xi'an,Xi'an, Shaanxi 710016
摘要【目的】探讨中药联合紫杉醇与卡铂治疗晚期卵巢癌的疗效以及对肿瘤相关标记物的影响。【方法】本院收治的80例晚期卵巢癌患者随机分为对照组和观察组。对照组采用紫杉醇与卡铂治疗,观察组在对照组的基础上自拟中药治疗。比较两组临床疗效,血清CA125、CA199,人附睾蛋白4(HE4)的变化以及对患者免疫功能的影响,并记录两组患者的并发症发生情况。【结果】观察组治疗有效率明显高于对照组(92.50% vs 75.00%)(P<0.05);治疗前两组CA125、CA199、HE4等指标水平相比较差异无显著性(P>0.05);治疗后观察组CA125、CA199、HE4水平明显优于对照组(P<0.05);两组患者化疗后CD3+、CD4+、CD8+、CD4+/CD8+水平均较化疗前变差(P<0.05);但化疗后观察组CD3+、CD4+、CD8+、CD4+/CD8+水平优于对照组(P<0.05);观察组不良反应发生率明显低于对照组(30.00% vs 57.50%)(P<0.05)。【结论】采用中西医结合的方式治疗晚期卵巢癌患者,可有效提高临床疗效、改善患者的免疫功能,最终改善患者的预后。
Abstract：【Objective】To explore the efficacy of Chinese medicine combined with paclitaxel and carboplatin in the treatment of advanced ovarian cancer and its effect on tumor-associated markers. 【Methods】A total of 80 patients with advanced ovarian cancer in our hospital were randomly divided into control group and observation group. The control group was treated with paclitaxel and carboplatin while the observation group was treated with traditional Chinese medicine on the basis of the same chemotherapy as the control group. The clinical efficacy, serum CA125, CA199, human epididymis protein 4(HE4) and the effect on immune function of the two groups were compared. The complications of the two groups were recorded. 【Results】The clinical efficacy of the observation group was significantly higher than that of the control group(92.50% vs 75.00%)(P<0.05);There was no significant difference in the levels of CA125, CA199 and HE4 between the two groups before treatment(P>0.05).After treatment, the levels of CA125, CA199 and HE4 in the observation group were significantly better than those in the control group(P<0.05).After chemotherapy, the levels of CD3+, CD4+, CD8+, CD4+/CD8+ in both groups were worse than before chemotherapy(P<0.05), but after chemotherapy, the levels of CD3+, CD4+, CD8+, CD4+/CD8+ in the observation group were better than those in the control group(P<0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group(30.00% vs 57.50%)(P<0.05). 【Conclusion】The combination of traditional Chinese and Western medicine in the treatment of patients with advanced ovarian cancer can effectively improve the clinical efficacy, improve the immune function of patients, and ultimately improve the prognosis of patients.
陈志梅. 中药组方联合紫杉醇与卡铂治疗晚期卵巢癌的疗效及对肿瘤标记物的影响[J]. 医学临床研究, 2021, 38(7): 998-1001.
CHEN Zhi-mei. Efficacy and Tumor-associated Markers Analysis of Chinese Medicine Combined with Paclitaxel and Carboplatin in the Treatment of Advanced Ovarian Cancer. JOURNAL OF CLINICAL RESEARCH, 2021, 38(7): 998-1001.
[1] 李桂梅, 刘冬梅, 平伟,等. 紫杉醇脂质体联合卡铂与紫杉醇联合卡铂治疗卵巢癌的疗效比较[J].中国肿瘤临床与康复, 2016,22(5):563-565. [2] 高翔, 刘永军, 于华,等. 不同剂量紫杉醇联合卡铂治疗晚期卵巢癌的疗效比较[J].山东医药, 2015,58(37):69-70. [3] 杨学宁, 吴一龙. 实体瘤治疗疗效评价标准—RECIST[J].循证医学, 2004, 4(2):85-90. [4] HAINSWORTH J D, THOMPSON D S, BISMAYER J A, et al. Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage Ⅲ/Ⅳ epithelial ovarian cancer:a randomized phase Ⅱ study of the Sarah Cannon Research Institute[J].Cancer Med,2015, 4(5):673-681. [5] 侯文杰, 徐建英, 池迟,等. 脂质体紫杉醇联合卡铂与紫杉醇联合卡铂治疗上皮性卵巢癌的疗效和安全性比较[J].肿瘤防治研究, 2018, 45(6):410-413. [6] 秦贞立, 方英姬, 黄晓戈. 紫杉醇联合卡铂治疗卵巢癌的效果分析[J].实用癌症杂志, 2015,30(2):286-287. [7] MEERPOHL H G, DU B A, LUCK H J, et al. Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer:a phase I trial[J].Semin Oncol,1997, 24(1 Suppl 2):S2. [8] 郭凤, 黄伟, 赵莉,等. 白蛋白结合型紫杉醇联合卡铂在晚期、复发性上皮卵巢癌治疗中的应用价值[J].实用癌症杂志, 2018,33(1):156-158. [9] 汪涛, 吕遐智, 王萍,等. 紫杉醇联合卡铂治疗卵巢癌的临床疗效及对患者血清CA125、CA199、CEA水平的影响[J].现代生物医学进展, 2018, 18(18):207-210. [10] 唐慕菲, 朱余兵, 李杨,等. 紫杉醇脂质体与紫杉醇分别联合卡铂治疗卵巢癌疗效的Meta分析[J].中国药师, 2018, 21(4):657-661. [11] 范淑英, 王健, 刘芸,等. 紫杉醇联合卡铂周疗和三周疗法治疗卵巢癌的Meta分析[J].解放军医学杂志, 2016, 41(7):589-597.
2021, Vol. 38 
